Fig. 7

Evidence of p-Tau pathology in oligodendrocytes in female mice exposed to GW toxic exposure with and without a history of r-mTBI. Representative images of immunofluorescence staining of the astrocyte marker GFAP, a marker of oligodendrocyte Oligo-2, and phosphorylated Tau CP13 (pSer-202) in the cortex/CC/hippocampal of female mice euthanized at 5 months post GW agent treatment (a, b). No difference between male and female mice was observed. Mice with a history of r-mTBI prior GW agent exposure qualitatively show an increased reactive astrogliosis in the three sub regions of the corpus callosum and in the hippocampus. In the body of the corpus callosum, co-labeling for p-Tau CP13 and Oligo-2 was found in all r-mTBI and GW groups (g–r). No Tau immunofluorescence was observed in the Sham/Vehicle animals (d). p-Tau staining in the r-mTBI/GW group was always markedly increased and more abundant than any of the other groups (p). In the magnified insets (j, h, r) the nuclear marker of oligodendrocytes Oligo2 establishes the co-localization with the aggregation of cytoplasmic p-tau CP13 characteristic of an “olicap” structure